Related Experiment Video
Updated: Sep 30, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Clinical Experience With RIST-Based Multimodality Therapy in Relapsed Ewing Sarcoma: A Descriptive Single-center Case
Mahdi Asleh1,2, Yotam Eshel1,2, Miriam Ben Harosh1,2
1Department of Pediatric Hemato-oncology, Saban Pediatric Medical Center, Soroka University Medical Center.
Background:
Outcomes for relapsed Ewing sarcoma remain poor. The RIST regimen (rapamycin, irinotecan, dasatinib, temozolomide) provides a targeted biological alternative to standard salvage chemotherapy.
Methods:
We report 3 patients treated with RIST for relapsed Ewing sarcoma.Results:One patient with measurable disease achieved an early partial response before progressing at 9 months. Two patients received RIST as post-local-therapy consolidation with no evidence of disease, maintaining disease control for 41 and 44 months. Toxicities were manageable and primarily hematologic, without treatment discontinuations.
Conclusion:
Prolonged outpatient RIST administration is feasible, and its role as multimodality consolidation warrants further prospective evaluation.